Viking Therapeutics, Inc.
US ˙ NasdaqCM ˙ US92686J1060

SecurityVKTX / Viking Therapeutics, Inc.
InstitutionAllworth Financial LP
Latest Disclosed Ownership2,280 shares
Latest Disclosed Value $ 74,200
Allworth Financial LP reports 115.09% increase in ownership of VKTX / Viking Therapeutics, Inc.

On May 14, 2026 - Allworth Financial LP filed a 13F-HR form disclosing ownership of 2,280 shares of Viking Therapeutics, Inc. (US:VKTX) valued at $74,191 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 1,060 shares of Viking Therapeutics, Inc.. This represents a change in shares of 115.09% during the quarter. The current value of the position is $66,872 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F VIKING THERAPEUTICS COM 92686J106 2,280 1,220 115.09 74 100.00 0.0003
2026-02-05 2025-12-31 13F VIKING THERAPEUTICS COM 92686J106 1,060 120 12.77 37 54.17 0.0002
2025-12-02 2025-09-30 13F VIKING THERAPEUTICS COM 92686J106 940 -15 -1.57 25 -4.00 0.0001
2025-08-07 2025-06-30 13F VIKING THERAPEUTICS COM 92686J106 955 352 58.37 25 66.67 0.0001
2025-04-30 2025-03-31 13F VIKING THERAPEUTICS COM 92686J106 603 126 26.42 15 -6.25 0.0001
2025-01-30 2024-12-31 13F VIKING THERAPEUTICS COM 92686J106 477 -11 -2.25 16 -46.67 0.0001
2024-10-23 2024-09-30 13F VIKING THERAPEUTICS COM 92686J106 488 6 1.24 31 25.00 0.0002
2024-07-24 2024-06-30 13F VIKING THERAPEUTICS COM 92686J106 482 15 3.21 25 -36.84 0.0002
2024-04-25 2024-03-31 13F VIKING THERAPEUTICS COM 92686J106 467 67 16.75 38 442.86 0.0003
2024-01-24 2023-12-31 13F VIKING THERAPEUTICS COM 92686J106 400 391 4,344.44 7 0.0001
2023-10-31 2023-09-30 13F VIKING THERAPEUTICS COM 92686J106 9 9 0 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.